Celltrion gets green light in EU for antibody drug

Published: 2013-08-30 07:00:00

Updated: 2013-08-30 07:00:00

Celltrion’s antibody drug Remsima won a final approval from the European Commission, the European Union’s executive arm, the company said Wednesday in its regulatory filing.

Celltrion officials said the EC’s approval will pave the way for the local drugmaker to export Remsima in 31 countries i...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK